Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 06:51 am Unchanged |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Dexcel Pharma Technologies Ltd. | 102,849,443 12.780% |
0 (Unchanged) |
Filing History |
| 2024-02-13 5:26 pm Sale |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Ramaswamy Vivek | 81,454,521 9.750% |
-328,720 (-0.40%) |
Filing History |
| 2024-02-13 5:00 pm Sale |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
SB Investment Advisers (UK) Limited | 73,031,667 9.100% |
-22,000,000 (-23.15%) |
Filing History |
| 2024-02-01 5:24 pm Sale |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Sumitomo Chemical Co. Ltd. | 71,251,083 8.860% |
-15,116,277 (-17.50%) |
Filing History |
| 2023-10-04 5:19 pm Purchase |
2023-10-02 | 13D | Immunovant, Inc. IMVT |
Roivant Sciences Ltd. ROIV |
79,815,331 55.300% |
6,416,667 (+8.74%) |
Filing History |
| 2023-06-26 5:05 pm Sale |
2023-06-22 | 13G | Roivant Sciences Ltd. ROIV |
VIKING GLOBAL INVESTORS LP | 75,238,700 9.900% |
-13,000,000 (-14.73%) |
Filing History |
| 2023-02-14 5:20 pm Purchase |
2022-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Ramaswamy Vivek | 81,783,241 10.900% |
7,381,272 (+9.92%) |
Filing History |
| 2023-02-14 4:08 pm Purchase |
2022-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Dexcel Pharma Technologies Ltd. | 102,849,443 14.150% |
4,040,285 (+4.09%) |
Filing History |
| 2023-02-14 4:08 pm Sale |
2022-12-31 | 13G | Roivant Sciences Ltd. ROIV |
SB Investment Advisers (UK) Limited | 95,031,667 13.100% |
-4,343,919 (-4.37%) |
Filing History |
| 2023-02-14 11:46 am Sale |
2022-12-31 | 13G | Roivant Sciences Ltd. ROIV |
QVT Financial LP | 122,541,536 16.890% |
-6,852,281 (-5.30%) |
Filing History |
| 2023-02-03 4:30 pm Unchanged |
2022-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Sumitomo Chemical Co. Ltd. | 86,367,360 11.910% |
0 (Unchanged) |
Filing History |
| 2022-02-14 5:01 pm Purchase |
2021-12-31 | 13G | Roivant Sciences Ltd. ROIV |
VIKING GLOBAL INVESTORS LP | 88,238,700 12.800% |
88,238,700 (New Position) |
Filing History |
| 2022-02-14 4:01 pm Purchase |
2021-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Ramaswamy Vivek | 74,401,969 10.500% |
74,401,969 (New Position) |
Filing History |
| 2022-02-14 3:00 pm Purchase |
2021-12-31 | 13G | Roivant Sciences Ltd. ROIV |
QVT Financial LP | 129,393,817 18.700% |
129,393,817 (New Position) |
Filing History |
| 2022-02-14 09:57 am Purchase |
2021-12-31 | 13G | Roivant Sciences Ltd. ROIV |
SB Investment Advisers (UK) Limited | 99,375,586 14.400% |
99,375,586 (New Position) |
Filing History |
| 2022-02-10 4:26 pm Purchase |
2021-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Dexcel Pharma Technologies Ltd. | 98,809,158 14.280% |
98,809,158 (New Position) |
Filing History |
| 2022-02-01 4:06 pm Purchase |
2021-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Sumitomo Chemical Co. Ltd. | 86,367,360 12.480% |
86,367,360 (New Position) |
Filing History |
| 2021-10-20 5:13 pm Purchase |
2021-10-18 | 13D | Arbutus Biopharma Corporation ABUS |
Roivant Sciences Ltd. ROIV |
38,847,462 29.100% |
22,833,922 (+142.59%) |
Filing History |
| 2021-08-02 08:23 am Purchase |
2021-08-02 | 13D | Immunovant, Inc. IMVT |
Roivant Sciences Ltd. ROIV |
73,398,664 63.800% |
17,021,276 (+30.19%) |
Filing History |
| 2021-03-08 08:00 am Unchanged |
2021-03-08 | 13D | Immunovant, Inc. IMVT |
Roivant Sciences Ltd. ROIV |
56,377,388 57.500% |
0 (Unchanged) |
Filing History |